By Rory McCann, Marketing Manager & Conference Producer, LSN
Eran is very active in the world of early-stage startups and fundraising within life science and is a recent contributor to the Redefining Early Stage Investments (RESI) community. Eran speaks with us about the value he’s found at RESI and how his many roles helped him make the most of his experience and add value to others.
Digital RESI takes place June 8-10. There’s still time to save on early bird rates, sign up by May 7 to save!
By Ashley Zborowski, Director of Business Development, LSN
The Redefining Early Stage Investment (RESI) Service Provider Showcase helps companies gain unprecedented visibility into the early-stage life science community and leverages Life Science Nation (LSN)’s close-knit network of key decision-makers to make promising connections with future clients. Service providers are an important asset in the fundraising ecosystem, and this new program is designed to increase their exposure to the RESI community.
Digital RESI, June 8-10, proudly features service providers advancing early-stage startups within drugs, devices, diagnostics, and digital health. Often the unsung heroes of fundraising startups, these powerful partnerships are essential in commercializing, building teams, conducting research, manufacturing, and so much more! Meet and get to know some featured service providers at Digital RESI June, and contact us to learn more about this special offer.
MERIT is an innovative specialty CRO providing clinical trial data collection and interpretation in the ophthalmology and respiratory disciplines. Our portfolio of solutions offers deep clinical expertise, unique technology, and exceptional service for our partners, sponsors, and CROs.
At PharmaDirections, gain access to top talent without the cost or risk of a full-time, in-house team. More than just a consultant or outside vendor, we are an extension of your team and are accountable for all aspects of a project, from discovery to regulatory approval.
SPH Phililab an innovation pharmaceutical company that develop, registrar, and manufacture generic and modified new drug product in USA and China. Our product portfolio focuses on the two largest pharmaceutical markets in the world, plus our unique background of management team and scientists made us a pioneer as an international player in the pharmaceutical industry.
By Rory McCann, Marketing Manager & Conference Producer, LSN
APIE Therapeutics is an early-stage company developing vascular endothelium niche repair and regeneration. We spoke with CEO, Dr. Esther Alegría about the early days of APIE Therapeutics and the importance of fit when seeking capital and building a powerful team.
APIE Therapeutics is an Innovator’s Pitch Challenge winner at last month’s Longevity, Health & Innovation, a Redefining Early Stage Investments (RESI) partnering event. Learn more about RESI and sign up by May 7 to save $50 on early bird rates.
RESI Longevity, September 16-17, is now accepting Innovator’s Pitch Challenge applications. Learn more and sign up by July 23 to save!
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Fundraising is a numbers game, and early-stage executives need to know that the odds are stacked in their favor when seeking capital and meeting with investors and strategic partners. Since Digital RESI March last year, 3,500+ investors from 700 unique firms have joined in Life Science Nation (LSN)’s virtual partnering events. Of these unique firms, over 70% have been repeat attendees and over half of those have attended more than five conferences since March 2020.
Investors are enthusiastically leveraging digital partnering to seek quality deal flow for potential investment, strategic partnership, in-licensing, and more. Fundraising executives aren’t the only ones who know partnering is a numbers game. They are showing up consistently to connect with the latest technology in drugs, devices, diagnostics, and digital health. To learn more, get involved, and take advantage of these trends, contact the RESI team and check out the upcoming Digital RESI, June 8-10.
By Caitlin Dolegowski, Marketing Specialist, LSN
Life Science Nation (LSN) renames its two newest conferences under the Redefining Early Stage Investments (RESI) banner. This conference series has provided early-stage life science entrepreneurs a space dedicated to their fundraising efforts through connecting them with partners and capital that are a fit for their product and stage of development. Through the years, LSN has worked with thousands of executives in their search for partnerships, and the secret has always been that it all comes down to finding that right fit. In order to help target these elusive matches, LSN spun two sister conferences, 4D Meets AI and Longevity, Health and Innovation, now RESI AI and RESI Longevity respectively, out of the RESI conference series, designed to further narrow down the early-stage life science players, based on technology and indication.
4D Meets AI has focused on connecting entrepreneurs using AI technology to advance drugs, devices, diagnostics, and digital health (4Ds) with investors and partners actively seeking AI applications in their themes and portfolios. Longevity, Health & Innovation, co-organized with Mary Furlong & Associates, is a space for fundraising executives targeting diseases that disproportionately affect aging populations to connect with capital and resources specifically in age-tech.
These two conferences are designed to create a more intimate atmosphere within the RESI partnering ecosystem. Each invites a unique attendee, yet both are a digital partnering conferences advancing the mission of the RESI series – to connect technology in life science and health care with well-fitting capital and channel partners – which is why they return this fall as RESI AI and RESI Longevity.
RESI Longevity and RESI AI both take place September 16-17 as two-day digital partnering conferences. Each will feature their own unique lineups of Investor Panels, Educational Workshops, Innovator’s Pitch Challenges and Premier Partnering Platforms. Learn more about each conference and sign up by July 23 to save $100 on super early bird prices!
 |
 |
By Karen Deyo, Director of Investor Research, Israel BD, LSN
The Life Science Nation (LSN) team has already gathered an exciting lineup of panelists for our Digital Redefining Early Stage Investments (RESI) conference, taking place June 8-10. Whether from organizations that have contributed to RESI in the past, or those speaking for the first time, panelists will contribute dynamic conversations and provide useful tips for fundraising startups. Here is a spotlight on some of the speakers who will be joining us in June!
 |
 |
 |
| Faz Bashi Member of BOD Life Science Angels |
Anna Turetsky Principal, Venture Investments The Mark Foundation for Cancer Research |
Juan Cueva Senior Associate Action Potential Venture Capital |
 |
 |
 |
| Miles Gerson Partner Takeda Ventures |
Sam Goldberger Partner Ambit Health Ventures |
Brian Meshkin Managing Partner, Profound Ventures Partner, Cancer Fund |
 |
 |
 |
| John Parker Founder & Managing Director Springhood Impact Ventures |
Richard Proscia Senior Associate Providence Ventures |
Yaniv Sneor Founding Member Mid Atlantic Bio Angels |
Register by May 7 to save $50 and hear from these panelists and to schedule meetings with the below investors who are participating in RESI!
*April 15, 2021
By Rory McCann, Marketing Manager & Conference Producer, LSN
Panaceutics Rx is an early-stage company advancing accessible personalized medicine based on patients’ digital health profiles using robotic platforms and patented processes.
We spoke with Panaceutics CEO, Edison Hudson about the need for more accessible adherence to life-saving therapies and Panaceutics’ approach to working with hospitals, investors, and physicians.
Panaceutics Rx is an Innovator’s Pitch Challenge winner at last month’s Longevity, Health & Innovation, a Redefining Early Stage Investments (RESI) partnering event. Learn more about RESI and sign up by May 7 to save $50 on early bird rates.
Next Phase Newsletter 